Early into an important launch for Emgality and amid rollouts for other key meds, Eli Lilly Bio-Medicines chief Christi Shaw is stepping aside.
Shaw will work with the drugmaker through the end of August and then will be replaced by Lilly’s top exec in Japan, Patrik Jonsson. The position is critical because many of Lilly’s growth drivers fall under Bio-Medicines, particularly after the surprise withdrawal of cancer med Lartruvo.
For example, Shaw is managing the rollout for new CGRP migraine prevention and cluster headache drug Emgality, which won a third-in-class approval last year but is charging ahead against drugs from Amgen and Teva.
And aside of Emgality, Shaw heads up commercialization for plaque psoriasis and psoriatic arthritis drug Taltz, one of Lilly’s top new drugs. It grew sales 68% last year to $937 million. Her group is also gearing up for the potential rollout of acute migraine drug lasmiditan plus pain med tanezumab in a partnership with Pfizer, among other pipeline meds.
Investors didn’t like the news. Lilly’s shares were down about 4% on Thursday morning after the announcement hit. It’s worth noting that shares for many pharma companies were down Thursday after the White House pulled the industry’s favored rebate proposal. Along with Shaw’s move, Lilly said its SVP and general counsel Mike Harrington would retire at the end of the year.
In its statement, Lilly CEO David Ricks said the Bio-Medicines division, under Shaw’s watch, “launched multiple new medicines globally, such as Olumiant and Emgality, and added key development projects to our early and late phase portfolio.”
“I value the external perspective and passion for patients that Christi brought to the company,” he added. Shaw took the Lilly post in April 2017 after leaving Novartis a year earlier for family reasons.
Before her current Lilly stint, Shaw worked at the Indianapolis drugmaker from 1989 to 2002 in sales and marketing. She also has experience with Johnson & Johnson. Lilly didn’t give a reason for her departure.
By Eric Sagonowsky
Source: Fierce Pharma
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
